Welcome to our dedicated page for Mind Medicine news (Ticker: MNMD), a resource for investors and traders seeking the latest updates and insights on Mind Medicine stock.
Mind Medicine Inc. (MNMD) is a clinical-stage biotech company pioneering research into psychedelic-inspired therapies for mental health disorders. This dedicated news hub provides investors and researchers with timely updates on MNMD's scientific advancements, regulatory milestones, and strategic initiatives.
Access official press releases detailing clinical trial progress, partnership announcements with leading research institutions, and analyses of the company's novel approaches to treating conditions like addiction and depression. Our curated collection ensures you stay informed about MNMD's work developing therapies that target neuroplasticity through compounds such as LSD-analogs and psilocybin derivatives.
Key updates include Phase 2 trial results, intellectual property developments, executive leadership changes, and presentations at major medical conferences. All content is sourced from verified channels to maintain compliance with financial disclosure standards.
Bookmark this page for streamlined access to MNMD's evolving story in psychedelic medicine. Check regularly for critical updates about FDA-regulated research programs and breakthrough therapy designation tracking within this emerging biopharmaceutical sector.
MindMed (NASDAQ: MNMD) has appointed Matt Wiley as Chief Commercial Officer (CCO) to oversee the company's commercial strategy as it prepares for the potential launch of MM120, an orally disintegrating tablet for generalized anxiety disorder (GAD) and major depressive disorder (MDD).
Wiley brings over 25 years of experience in sales, marketing, and strategic leadership across multiple specialty product launches. He previously served as CCO at BioXcel Therapeutics and VYNE Therapeutics, and as Vice President of Marketing at Jazz Pharmaceuticals where he led XYREM® to blockbuster status.
As part of his appointment, Wiley received inducement awards including:
- 350,000 common share options vesting over four years
- 125,000 performance stock units (PSUs) vesting on the third anniversary, with potential earnings of 0-200% based on performance metrics
MindMed (NASDAQ: MNMD) reported its Q4 and full-year 2024 financial results, highlighting significant progress in its clinical programs. The company has $273.7 million in cash as of December 31, 2024, following successful equity financings totaling $250 million, extending operations into 2027.
Key developments include: First patients dosed in Phase 3 Voyage and Panorama studies of MM120 ODT for Generalized Anxiety Disorder (GAD), with topline data expected in 1H 2026 and 2H 2026 respectively. The company plans to initiate Emerge, the first Phase 3 study for Major Depressive Disorder (MDD), in 1H 2025.
Financial highlights:
- R&D expenses increased to $65.3 million in 2024 from $52.1 million in 2023
- G&A expenses decreased to $38.6 million in 2024 from $41.7 million in 2023
- Net cash used in operations was $79.1 million in 2024 versus $64.4 million in 2023
MindMed (NASDAQ: MNMD), a late-stage clinical biopharmaceutical company focused on brain health disorders, has announced its participation in the upcoming Leerink's Global Healthcare Conference 2025. The company's management team will engage in a fireside chat and one-on-one meetings at the event, scheduled for March 11, 2025, at 3:40 PM ET in Miami Beach, FL.
Interested parties can access the presentation through a webcast, with audio recordings and replays remaining available on MindMed's Investor Relations website for up to 90 days after the event.
MindMed (MNMD), a late-stage clinical biopharmaceutical company focused on brain health disorders, has announced it will host a live webcast on March 6, 2025, at 8:00 a.m. ET. During the webcast, the company will present its fourth quarter and full-year 2024 financial results and provide business updates.
The webcast will be accessible through a registration link, with a separate link provided for analysts who wish to participate in the Q&A session. Participants are advised to join 15 minutes before the start time. A replay will be available through MindMed's Investor Relations website and will be archived for at least 30 days.
MindMed (NASDAQ: MNMD), a late-stage biopharmaceutical company focused on brain health disorders, has announced its participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference. The company's management team will engage in a fireside chat and one-on-one meetings during the virtual event, scheduled for February 12, 2025, at 9:20 AM ET.
Audio webcasts and replays of the presentations will be made available on MindMed's Investor Relations website, remaining accessible for up to 90 days after the event. This conference participation represents an opportunity for the company to showcase its developments in brain health treatments to the investment community.
MindMed (NASDAQ: MNMD) has initiated Panorama, its second Phase 3 study of MM120 ODT (lysergide D-tartrate) for Generalized Anxiety Disorder (GAD), with the first patient now dosed. The study will evaluate a proprietary, pharmaceutically optimized form of LSD against placebo, enrolling approximately 250 participants across US and Europe.
The 52-week trial consists of two parts: a 12-week double-blind, placebo-controlled period and a 40-week extension period for open-label treatment. Participants will be randomized in a 2:1:2 ratio to receive MM120 ODT 100 µg, 50 µg, or placebo. The primary endpoint will measure changes in Hamilton Anxiety Rating Scale (HAM-A) score at week 12.
The study builds on positive Phase 2b results presented at the American Psychiatric Association's Annual Meeting in May 2024. Topline data from the 12-week double-blind period is expected in the second half of 2026.
MindMed (MNMD) announced its upcoming addition to the Nasdaq Biotechnology Index (NBI), effective December 23, 2024. The company highlighted key 2024 achievements, including raising $250 million through equity financings, securing a new patent for MM120 orally disintegrating tablet (ODT) with protection through 2041, expanding their pipeline to include MM120 ODT for major depressive disorder, and launching Phase 3 Voyage study for generalized anxiety disorder. The NBI tracks biotechnology and pharmaceutical securities on Nasdaq, with companies meeting specific eligibility criteria including market capitalization, trading volume, and public company seasoning requirements.
MindMed (NASDAQ: MNMD) has initiated its Phase 3 Voyage study by dosing the first patient with MM120 ODT, a pharmaceutically optimized form of lysergide D-tartrate (LSD) for treating Generalized Anxiety Disorder (GAD). The study, designed to enroll approximately 200 participants in the U.S., is the first of two Phase 3 trials. The 52-week study consists of a 12-week double-blind period and a 40-week extension period. The primary endpoint will measure changes in HAM-A scores at Week 12.
The second Phase 3 trial, Panorama, is scheduled to begin in the first half of 2025 across the U.S. and Europe. These trials build upon positive Phase 2b results presented at the American Psychiatric Association's Annual Meeting in May 2024. Topline data from the 12-week double-blind period is expected in the first half of 2026.
Mind Medicine (MindMed) (NASDAQ: MNMD), a clinical-stage biopharmaceutical company, announced the presentation of encore data from its Phase 2b study of MM120 (lysergide D-tartrate or LSD), the company's lead product candidate for treating generalized anxiety disorder (GAD), at the ACNP 2024 Congress held from December 8-11 in Phoenix, AZ.
The presentations included two posters:
- Functional and sexual disability, and quality of life after one dose of MM120 (lysergide) in adults with GAD, presented by Paula Jacobson, Ph.D., Executive Director, Clinical Development, MindMed.
- Rapid and durable response to a single dose of MM120 (lysergide) in GAD: A dose-optimization study, presented by Dan Karlin, M.D., M.A., Chief Medical Officer, MindMed.
The posters are available on MindMed’s Company website.
Mind Medicine (MindMed) (NASDAQ: MNMD), a clinical-stage biopharmaceutical company, announced that its MM120 Orally Disintegrating Tablet (ODT) has been granted an Innovation Passport by the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) under the Innovative Licensing and Access Pathway (ILAP). This designation aims to accelerate the time to market and facilitate patient access to MM120 ODT for the treatment of Generalized Anxiety Disorder (GAD). The Innovation Passport provides access to various development tools and opportunities for enhanced regulatory input. Specific benefits include a potential 150-day accelerated Marketing Authorization Application assessment and continuous benefit-risk assessment. This follows the receipt of Breakthrough Therapy Designation by the U.S. FDA, highlighting MM120 ODT's potential to address critical needs in mental health.
FAQ
What is the current stock price of Mind Medicine (MNMD)?
What is the market cap of Mind Medicine (MNMD)?
